At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 100 target
Drug / intervention
HPV-CTLsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II and Multicenter Trial of HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of Human Papilloma Virus (HPV) Infection
In Brief
A Phase 1 clinical trial evaluating HPV-CTLs for Human Papilloma Virus. Currently recruiting, targeting 100 participants across 1 site.
Detailed Summary
The purpose of this clinical trial is to evaluate the safety and efficacy of IV-infused autologous or allogenic HPV-CTLs.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Papilloma Virus
CountriesChina
Collaborators--
Timeline
Phase 1Recruiting
20182019202020212022202320242025202620272028202920302031
First PostedNov 2017
Enrollment StartJun 2026
TodayJul 2026
Primary CompletionDec 2029
Study CompletionDec 2030
First PostedNov 24, 2017
Enrollment StartJun 1, 2026
Primary CompletionDec 31, 2029
Study CompletionDec 31, 2030
TodayJul 1, 2026
Enrollment to primary: 3.6 yearsPosted 8.6 years agoPrimary completion in 3.5 years
Arms & Interventions
HPV-CTLsexperimental
Autologous or allogenic HPV specific cytotoxic lymphocytes
Biological: HPV-CTLs
Interventions
HPV-CTLsbiological
2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg by IV each time